title: [Quality of life in patients with renal carcinoma].
abstract: First line treatment of renal cell carcinoma (RCC) is radical nephrectomy. In patients with metastasis or with local recurrence adjuvant immunohaemiotherapy is necessary. Interferon alpha is used with or without Interleukin 2 in combination with cytostatics. Immunotherapy induces some adverse effects which might compromise the treatment. The aim of this pilot study was to asses the effect of interferon on the quality of life in patients with RCC previously treated with radical nephrectomy. The originally made questionnaire was used to measure the impact of the treatment on quality of life of 15 patients. It was that Interferon did not alter significantly the quality of life in examined patients.
authors.forename: V
authors.initials: V
authors.lastname: Vukotić-Maletić
authors.forename: B
authors.initials: B
authors.lastname: Stojković-Djordjević
authors.forename: J
authors.initials: J
authors.lastname: Hadzi-Djokić
authors.forename: D
authors.initials: D
authors.lastname: Dragićević
mesh_terms: D002292:Carcinoma, Renal Cell / Q000523:psychology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000523:psychology / Q000628:therapy*; D008297:Male; D009392:Nephrectomy; D011788:Quality of Life